Mirati jumps after FDA approves lung cancer drug

Mirati Therapeutics

13/12/2022 12:14

** Shares of Mirati Therapeutics Inc  MRTX.O  rise ~10% to
$45.5 premarket
    ** Co late on Monday said the U.S. Food and Drug
Administration had approved co's lung cancer drug 
    ** SVB Securities analysts say the drug's safety label is
better than the brokerage's expectations 
    ** Drug will be sold under the brand name Krazati, priced
$19,750 for a 200 milligram tablet/180 count bottle - MRTX
    ** Krazati has been approved for treating adult patients
with advanced lung cancer, as determined by an FDA-approved
test, who have received at least one prior systemic therapy
   ** Up to Monday's close, stock had fallen ~72% YTD 
 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))